Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsEmerging drugs and vaccines for candidemiaIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentImpact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.In vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation studyUncommon opportunistic yeast bloodstream infections from Qatar.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisDevelopments in the treatment of candidiasis: more choices and new challenges.Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Current options in antifungal pharmacotherapy.Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.New and investigational triazole agents for the treatment of invasive fungal infections.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.New generation azole antifungals in clinical investigation.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Dosing of antifungal agents in obese people.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Systemic Antifungal Agents: Current Status and Projected Future Developments.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry
P2860
Q26740837-ABA43570-1D04-4371-9D53-B0947E0D3811Q26744049-F4E5BEB4-54EA-4E2C-A4EF-C192CC45667DQ26828993-D0AF2B66-8313-49EB-B29D-12EC04522110Q28067726-74FC24EC-7774-4FED-88CD-7E8FD0FF5876Q28082019-4C6A9F41-79D4-484F-B451-917942222770Q33726698-4D9AE34C-7A6B-436F-A81B-179509ACA0F5Q34298778-A9C2D8B2-3332-49CB-89DD-B7B9019F0F00Q34474946-48333790-9ACF-47ED-929A-783989961FB6Q34900399-5910D746-E324-432D-AD61-F7CC9C41425CQ35168889-6173E855-0D6C-4F73-9BE8-93D347BAC068Q35189199-3F3476FE-9C60-454C-AD7A-231EF147EA83Q35385554-0623A839-702A-47E6-B62D-7E80C191A0C1Q36396166-D355AB86-4027-4957-BC93-9D4AC72F8CB1Q36439102-120E8F4E-AF2B-4681-8377-2DDE5B716C66Q36623050-45445186-3261-4249-8B18-000B17B4B8D8Q36887855-A6C5765C-D9A8-4937-9A36-0B9BA4D17C6EQ37036173-1CF51D86-8C87-4890-81A7-5AF271AE5063Q37151326-9DAC97C3-4848-490D-B877-9FFC13C394E4Q37203893-82ED6103-283B-4123-A184-4ABB90D59A48Q37263435-48C09DF8-0737-414F-8CFD-0497C9F41F2AQ37335649-99BE1D2C-2E02-4FAA-A16C-786E4B2F0F43Q37364295-46041114-5711-44B4-A466-9E9A4551DDE7Q37409882-910BD755-DEFD-4AC2-8B93-9DE9FB7A120AQ37579222-676324F2-21AD-490B-9287-A52F89B9E49CQ37918556-879D05F9-EEE6-442B-9DA5-8CE652F0C091Q38005226-5133E180-A5EC-424A-AC95-E8EFBCB52FE4Q38159688-F91BA528-4662-4749-BF7A-C556DB4932C9Q38285488-8033DC7D-CD9F-4CB8-993F-F16DB68E2EE4Q38436002-18D6484B-0542-4101-954F-2ED0DC89ABB6Q38534865-A20F4A63-5FA9-4279-86A6-7EB81B15434DQ38644817-C5019C1D-A9CE-4028-9024-9B6544A6694DQ38660761-96D94575-B33D-4E00-A467-A0DCE5BF575DQ38681635-7E48D71E-09A9-4B2B-B4BA-74B5AA2C7ABEQ38738090-A978CEA0-2CA9-4B4C-B284-3ABE145D8A87Q38796140-D5AC1DEF-9873-4063-B432-B2B5DE98F498Q38829932-CED12B98-6136-4757-BDAF-553379A9710BQ38939506-6ADF5B5F-FAA9-4D36-9191-A7C6FB2AF1D2Q38987096-4C8B8CA6-6954-4B42-8C7A-1258D75E87D1Q39003715-120E005F-E034-4D26-AD03-4AC951284EADQ40337647-6960AE58-818C-48A6-AD7F-CCDBD0FF3CB1
P2860
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@nl
type
label
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@nl
prefLabel
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@nl
P2093
P2860
P1476
Multiple-dose pharmacokinetics ...... AL8557, in healthy volunteers.
@en
P2093
Anne Schmitt-Hoffmann
Brigitte Roos
Erhard Weidekamm
Jochen Spickerman
Jürgen Maares
Markus Heep
Michael Roehrle
P2860
P304
P356
10.1128/AAC.50.1.286-293.2006
P407
P577
2006-01-01T00:00:00Z